Sandhoff Disease: The GM2 Gangliosidosis Caused by HEXB Variants

Table of Contents

1. A Rare Disease of Stored Fat in Nerve Cells
2. The HEXB Gene and the Loss of Two Enzymes
3. How GM2 Builds Up in Nerve Cells
4. The Infantile Form
5. The Juvenile Form
6. The Late-Onset Form
7. Communities With More Cases
8. Diagnosis: Both Enzymes and the Gene
9. Inheritance and Carrier Testing
10. Supportive Care Described in GeneReviews
11. Miglustat: Lowering the Supply of Stored Fat
12. N-Acetyl-L-Leucine and Pyrimethamine
13. Gene Therapy Results So Far
14. What Is Not Known
15. Key Research Papers
16. Connections
17. Featured Videos

A Rare Disease of Stored Fat in Nerve Cells

Every cell has small recycling compartments called lysosomes. Enzymes inside them take apart worn-out molecules so the pieces can be reused. Sandhoff disease is one of the lysosomal storage disorders: one recycling step fails, and the molecule that would normally be taken apart piles up instead.

The molecule that piles up in Sandhoff disease is GM2 ganglioside, a fat-and-sugar molecule that is a normal part of nerve-cell membranes. The enzyme family that trims it is called beta-hexosaminidase. A 1999 mouse study summarised the problem in one line: in Sandhoff disease “GM2 ganglioside fails to be degraded and accumulates within lysosomes in cells of the periphery and the central nervous system.”

The 2022 GeneReviews chapter on Sandhoff disease, written by clinicians at the US National Human Genome Research Institute, describes the disease as a continuum rather than three separate illnesses. It still uses three labels because they help explain the range of ages at onset, first signs, speed of progression and life span:

• Acute infantile — onset before 6 months of age.
• Subacute juvenile — onset at 2 to 5 years.
• Late-onset — onset in the older teen years or young adulthood.

The chapter calls the split between these groups “somewhat arbitrary.” Patients do not always fit neatly into one box.

Back to Table of Contents

The HEXB Gene and the Loss of Two Enzymes

Beta-hexosaminidase comes in two main working forms in the body, and both are built from small protein pieces called subunits:

• Hexosaminidase A is made of one alpha subunit and one beta subunit. It is the form that can break down GM2 ganglioside.
• Hexosaminidase B is made of two beta subunits. It acts on other sugar-containing molecules.

The alpha subunit is made from the HEXA gene. The beta subunit is made from the HEXB gene. A 2011 clinical trial report put it directly: late-onset GM2 gangliosidosis results “from mutations in the HEXA (Tay-Sachs variant) or the HEXB (Sandhoff variant) genes,” and mutations in “either the α or β subunit of Hex A” can reduce the enzyme.

That shared beta subunit is the whole difference between the two diseases:

• In Tay-Sachs disease the alpha subunit is faulty. Hexosaminidase A is lost, but hexosaminidase B (beta plus beta) still works.
• In Sandhoff disease the beta subunit is faulty. Because both enzymes need it, both hexosaminidase A and hexosaminidase B are lost.

This is why the laboratory picture is different. In the Iranian series of 25 infants described below, “enzyme studies showed marked reductions of both Hexosaminidase A and B in all patients.” In Tay-Sachs disease, total hexosaminidase activity can look normal because hexosaminidase B is still present; the Tay-Sachs page covers that side of the comparison.

Many different HEXB variants exist. In the Iranian infant series, gene testing in 8 patients found 6 different variants, 5 of them never reported before. A Saskatchewan screening study found 4 disease-causing variants in one region, 2 of them new.

Back to Table of Contents

How GM2 Builds Up in Nerve Cells

Nerve cells carry a great deal of ganglioside in their membranes and keep renewing it. When the trimming step is missing, GM2 has nowhere to go and collects inside the lysosomes. The juvenile natural-history study describes the GM2 gangliosidoses as diseases “caused by deficiency of lysosomal beta-hexosaminidase resulting in GM2 ganglioside accumulation in brain.” The infantile natural-history study says the same of the infant form, which “leads to rapid neurodegeneration.”

Two features set Sandhoff disease a little apart from Tay-Sachs disease:

• Storage outside the brain. Because hexosaminidase B is also missing, storage is not limited to nerve cells. The 1999 mouse study reported storage “in cells of the periphery and the central nervous system,” and a 2026 study in cats with Sandhoff disease measured improvement in the liver after treatment (see Gene Therapy). In people, however, enlarged organs were uncommon: in the Iranian infant series, organ enlargement “was detected only in two patients” out of 25.
• Peripheral nerves. In the juvenile series, nerve damage outside the brain (neuropathy) was more common in Sandhoff patients than in Tay-Sachs patients, and in the French adult series, low sensory nerve signals were seen “mainly in the SD patients.”

Across the age groups, the most common brain scan finding in older patients is shrinkage of the cerebellum, the part of the brain that coordinates movement. It was the most common MRI finding (52.9%) in the juvenile series and “the main brain magnetic resonance imaging feature” in the adult series, “even in patients without cerebellar symptoms.”

Back to Table of Contents

The Infantile Form

The GeneReviews chapter describes infants with acute infantile Sandhoff disease as “generally normal at birth followed by progressive weakness and slowing of developmental progress, then developmental regression and severe neurologic impairment.” Seizures are common, and “death usually occurs between ages two and three years.”

The Iranian series of 25 infants

A 2018 report from the Iranian Neurometabolic Registry described 25 children with infantile Sandhoff disease diagnosed between December 2010 and December 2016 (13 girls and 12 boys):

• The mean age at first signs was 6.4 months; the mean age at diagnosis was 14 months, a mean delay of 7.8 months.
• The most common feature at presentation (92%) was developmental delay or loss of skills in speech and thinking.
• A cherry-red spot at the back of the eye was seen in 17 children (68%).
• Organ enlargement was seen in only 2 children.
• About 80% of the parents were related to each other by blood.
• Eleven of the children died, from aspiration pneumonia (food or fluid entering the lungs) and seizures that did not respond to treatment.

The North American survey of infantile GM2 gangliosidosis

A 2011 study in Pediatrics surveyed families of 237 children with infantile GM2 gangliosidosis through a US patient association, and had detailed histories for 97. It grouped Tay-Sachs and Sandhoff patients together, and reported that the two “did not differ.” Its findings:

• The common first signs were developmental arrest (83%), an exaggerated startle to sound (65%) and floppiness or low muscle tone (60%).
• All 55 children who had learned to sit without support lost that ability within 1 year.
• The authors described the disease as leading to death before 4 years of age.
• Placement of a feeding tube into the stomach was associated with longer survival.
• Five children who had received a blood stem cell (bone marrow) transplant were looked at separately; the transplant “was not associated with prolonged survival.”

The authors noted that how fast skills were lost did not predict how long a child lived, which they linked to improvements in supportive care over time.

Back to Table of Contents

The Juvenile Form

GeneReviews describes subacute juvenile Sandhoff disease as starting at 2 to 5 years, after normal early milestones. Progress slows, then skills are lost, with “abnormal gait, dysarthria, and cognitive decline.” Dysarthria is slurred or unclear speech. “Death (usually from aspiration) typically occurs in the early to late teens.”

The largest natural-history study of the juvenile form, published in 2006, followed 21 patients in two centres — 15 with the Tay-Sachs variant and 6 with the Sandhoff variant — and compared them with 134 patients described earlier. The figures below are for the whole group of 21, not for the Sandhoff patients alone:

• Mean age at first signs: 5.3 years (standard deviation 4.1), with a mean follow-up of 8.4 years.
• Most common first signs: walking problems (66.7%), poor coordination (52.4%), speech problems (28.6%) and developmental delay (28.6%).
• From the start of walking problems to needing a wheelchair took a mean of 6.2 years; from the start of speech problems to loss of speech (anarthria) took a mean of 5.6 years.
• Muscle wasting, weakness near the trunk and loss of bladder and bowel control came later.
• Median survival across the studied and reviewed patients was 14.5 years.

The study found real differences between the two variants: psychiatric disturbances and neuropathy were more common in the Sandhoff patients, while swallowing problems, loss of bladder and bowel control and sleep problems came earlier in the Tay-Sachs patients. In both groups, speech declined faster than walking.

Back to Table of Contents

The Late-Onset Form

In late-onset Sandhoff disease, GeneReviews describes “nearly normal psychomotor development” followed by neurological signs such as weakness, stiffness (spasticity), slurred speech and poor coordination, and psychiatric findings such as problems with planning and memory. The chapter states that “life expectancy is not necessarily decreased.”

A 2020 French study described 12 adult patients with GM2 gangliosidosis and 45 more from the medical literature, both Tay-Sachs and Sandhoff. It found four typical pictures:

1. A lower motor neuron disorder — weakness of the upper legs first, later spreading to the arms. The psoas (a deep hip muscle) was the first and most affected leg muscle.
2. Cerebellar ataxia — unsteady walking and poor coordination.
3. Psychosis and/or severe mood disorder — seen only in the Tay-Sachs patients in this series.
4. A mixed picture combining the three.

Nerve tests showed the motor signals falling over time, and sensory nerve signals were “sometimes abnormally low, mainly in the SD patients.” Walking was the main driver of disability: beyond 20 years of disease, half of the patients used a wheelchair.

Because adult GM2 gangliosidosis can look like motor neuron disease, it is sometimes discussed alongside amyotrophic lateral sclerosis and other causes of cerebellar ataxia. The GeneReviews chapter also lists certain psychiatric medicines — haloperidol, risperidone and chlorpromazine — that have been associated with worsening disease in late-onset Tay-Sachs disease, a similar disorder, under the circumstances it names for avoidance in late-onset Sandhoff disease.

Back to Table of Contents

Communities With More Cases

Sandhoff disease is rare worldwide, but screening studies show a few communities where one disease-causing variant has become common, usually through descent from a small group of shared ancestors:

• Maronite Christians of Cyprus. After four infants were diagnosed with Sandhoff disease in Cyprus over 15 years — three of them from the Maronite community — a 2000 screening study tested blood samples. Enzyme testing found 35 carriers among 244 random Maronite samples, but only 1 carrier among 115 random samples from the Greek Cypriot community. The authors estimated the Maronite carrier rate at about 1 in 7, and 42 of 50 Maronite carriers tested had the same single-letter deletion in HEXB.
• Northern Saskatchewan, Canada. A 2014 study re-tested stored newborn screening cards from northern Saskatchewan. The carrier rate for one variant (c.115delG) was about 1 in 27; for all four variants found, about 1 in 15. The authors estimated the disease rate at about 1 in 390 births, or one affected child every 1 to 2 years. The 1 in 15 carrier rate was more than 3 times the global estimate of 1 in 57 that the authors calculated from the 1000 Genomes project.
• Córdoba region of Argentina. A 1994 study of a population group in Argentina with a high rate of infantile Sandhoff disease found that 30 of 31 independent HEXB copies examined carried the same splice-site variant (IVS-2+1 G>A).

The Iranian infant series, where about 80% of parents were blood relatives, shows the other common route: a recessive disease appears more often when parents share ancestry. Unlike Tay-Sachs disease, none of these studies describe a raised rate of Sandhoff disease among Ashkenazi Jewish people.

Back to Table of Contents

Diagnosis: Both Enzymes and the Gene

The GeneReviews chapter gives two parts to the diagnosis in a person with signs of the disease:

1. Enzyme testing that finds abnormally low activity of both hexosaminidase A and hexosaminidase B, “combined with an increased contribution from HEX A.” In other words, the total is low, but the share of the remaining activity that comes from hexosaminidase A is higher than usual.
2. Genetic testing that finds disease-causing variants in both copies of HEXB.

This pattern is the main laboratory difference from Tay-Sachs disease, where hexosaminidase A is low but total hexosaminidase is not. The Saskatchewan study used the same logic in reverse to find carriers: it looked for “low total hexosaminidase activity and high % hexosaminidase A activity,” and then confirmed the result by sequencing the gene.

Other findings that point doctors toward the diagnosis are the ones described in the case series above: loss of skills in an infant, an exaggerated startle, a cherry-red spot at the back of the eye, and, in older patients, cerebellar shrinkage on MRI. None of these alone separates Sandhoff disease from Tay-Sachs disease; the enzyme and gene tests do.

Back to Table of Contents

Inheritance and Carrier Testing

Sandhoff disease is autosomal recessive: a child is affected only when both copies of HEXB, one from each parent, carry a disease-causing variant. Carriers, who have one working copy, have no symptoms. GeneReviews gives the standard odds when both parents are carriers: each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier, and a 25% chance of a child who inherits neither variant. Once the family’s variants are known, carrier testing for relatives and testing before birth or before embryo implantation become possible.

The screening studies show both the strength and the limits of enzyme-based carrier testing:

• In the Argentine study, among 57 unaffected members of affected families, there was “absolute correlation” between carrier results from the white-blood-cell enzyme test and the DNA test. The authors concluded that the DNA test “can be an effective supplement or alternative to enzyme-based testing.”
• In the Cyprus study, 8 Maronite samples called carriers by enzyme testing did not have either known variant. The authors wrote that these people may have been wrongly classed as carriers “since their enzyme values are equivocal,” although another variant was not ruled out.

Back to Table of Contents

Supportive Care Described in GeneReviews

The GeneReviews chapter states that “treatment is symptomatic.” It describes supportive care by form:

• Infantile form: adequate nutrition and fluids, management of infections, protecting the airway to lower the risk of aspiration, seizure control, support for motor development and prevention of joint and bone deformities. Among circumstances it lists for avoidance are feeding positions that raise aspiration risk and seizure-medicine doses that cause heavy sedation.
• Juvenile and late-onset forms: keeping movement and speech for as long as possible, and aids for daily living and communication. It names long periods without moving (which lead to stiff joints and pressure sores) and situations that raise the risk of falls, such as walking on uneven ground.

The chapter also describes regular check-ups by a team of specialists to track the disease and adjust care. The infantile natural-history study found that a feeding tube was associated with longer survival.

Back to Table of Contents

Miglustat: Lowering the Supply of Stored Fat

If the body cannot break GM2 down, one idea is to make less of it. This is called substrate reduction. Miglustat (chemical name N-butyldeoxynojirimycin) blocks glucosylceramide synthase, the enzyme that makes the first building block of this family of fats, and it crosses into the brain.

In mice

A 1999 study gave miglustat to a mouse model of Sandhoff disease. The treated mice had delayed onset of symptoms, less storage in the brain and other tissues, and a longer life span.

In people

• A pharmacology study in children (2009). Eleven children with infantile (6) or juvenile (5) GM2 gangliosidosis received miglustat by mouth at 30 to 200 mg three times a day, adjusted to body size, for up to 24 months. The drug had a half-life of about 10 hours. The main drug-related side effects were stomach discomfort and wind in the infants, and diarrhoea and weight loss in the juvenile group; the authors described the diarrhoea as controlled by changes to the diet. The abstract does not report how many of the children had Sandhoff disease, and the study was not designed to measure benefit.
• One juvenile Sandhoff patient in Norway (2009). A young man whose clumsiness and slurred speech began at 2 to 3 years was diagnosed at 16. After 2.5 years of miglustat, his weight had stabilised and “disease progression appeared to have slowed,” judged by the lack of further brain shrinkage. His depression was treated with electroconvulsive therapy, which improved his general functioning.
• One adult Sandhoff patient in Italy (2010). A patient with a spinal-muscular-atrophy-like form received 100 mg three times a day for 3 years. The authors documented “some minor effects on neurological progression” and wrote that phase II trials in early-stage patients were needed to assess whether it works.
• A systematic review (2023). Reviewers pooled 10 articles and 2 conference abstracts covering 54 treated patients with GM2 gangliosidosis and 22 untreated comparison patients. Where the type was recorded, 14 had Sandhoff disease and 54 had Tay-Sachs disease. They concluded that miglustat is not “a definite treatment,” but that patients, “particularly those with infantile or late-infantile GM2g, could benefit from miglustat therapy to some extent.”

No randomised trial of miglustat limited to Sandhoff disease appears in these sources. The evidence in people is single-patient reports and small mixed groups.

Back to Table of Contents

N-Acetyl-L-Leucine and Pyrimethamine

N-acetyl-L-leucine

N-acetyl-L-leucine is a modified form of the amino acid leucine, taken by mouth. It does not replace the missing enzyme; it was studied for its effect on movement and coordination.

• Early signals (2021). A laboratory and clinical report found that the related mixture acetyl-DL-leucine had a beneficial effect on walking in a mouse model of Sandhoff disease, and in individual Tay-Sachs and Sandhoff patients who took it off-label.
• Phase IIb trial (2023). Thirty patients aged 6 to 55 years with genetically confirmed GM2 gangliosidosis took N-acetyl-L-leucine for 6 weeks (the trial gave 4 g a day to patients aged 13 and over, and weight-based doses to children aged 6 to 12), followed by 6 weeks off the drug. Blinded raters scored videos of a walking test or a peg-board test. Twenty-nine patients were analysed. The trial met its main measure: the mean difference was 0.71 (standard deviation 2.09; 90% confidence interval 0.00 to 1.50; p = 0.039). It also met its secondary measures of ataxia and overall impression. There were no serious adverse reactions.

The limits are part of the result. The trial was open-label (patients and doctors knew the drug was being given; only the video raters were blinded), had no placebo group, and lasted 6 weeks. The journal classed it as “Class IV evidence,” the lowest level in its scheme. The abstract reports results for GM2 gangliosidosis as a whole, not separately for Sandhoff patients. The same compound is discussed for another lysosomal disease on the Niemann-Pick type C treatments page.

Pyrimethamine

In many juvenile and adult patients, the faulty enzyme is made but folds badly and is destroyed before it reaches the lysosome. In cells, the older antiparasitic drug pyrimethamine helped some of these unstable enzymes reach the lysosome. A 2011 open-label phase I/II trial enrolled 11 adults aged 23 to 50 with late-onset GM2 gangliosidosis (Tay-Sachs or Sandhoff variants) for 16 weeks, raising the dose to a maximum of 100 mg a day. In the 8 patients analysed:

• White-blood-cell hexosaminidase A activity rose up to 4-fold at doses of 50 mg a day or less.
• Most patients had significant side effects at 75 mg a day or more.
• Clinical benefit could not be assessed in a trial this short.

Back to Table of Contents

Gene Therapy Results So Far

Gene therapy aims to give nerve cells working copies of the genes so they can make the enzyme themselves. The vectors used so far are built from an adeno-associated virus (AAV), a small virus that does not cause disease, emptied and loaded with the human gene. Because hexosaminidase A needs both subunits, the human programmes deliver HEXA and HEXB together.

Two Tay-Sachs children (2022)

The first human report treated two children with infantile Tay-Sachs disease (not Sandhoff) under expanded access, with safety as the main measure. Both received an equal mix of HEXA and HEXB adeno-associated virus vectors into the fluid around the brain and spinal cord, one also directly into both thalami (deep brain structures), and both received medicines to suppress the immune system. The procedures were well tolerated with no vector-related adverse events reported. Enzyme activity in the spinal fluid rose. The younger child showed stabilisation by 3 months, but “disease progression was evident at 6 months after treatment.”

Phase 1/2 trial including Sandhoff children (2025)

The follow-on phase 1/2 trial, published in Nature Medicine in 2025, treated children with Tay-Sachs and Sandhoff diseases — six infantile and three juvenile — with one dose into both thalami plus the spinal fluid, doubling the dose between four groups. The reported results:

• Spinal-fluid hexosaminidase A, blood total hexosaminidase and GM2 levels showed a dose-dependent biochemical correction. Blood hexosaminidase activity rose above 40 nmol per hour per mL, twice the lower limit of normal.
• The correction was greatest at 12 weeks and was declining by 24 weeks.
• The infants showed overall clinical stabilisation and kept feeding by mouth without aspiration until 3 to 3.5 years of age. Their seizures began later, were less frequent and less severe, and responded better to medicine.
• Adverse events were rare in the infants, but dystonia (abnormal muscle contractions) worsened in the juvenile patients, who were then excluded from further enrolment.

The abstract does not say how many of the nine children had Sandhoff disease, and there was no untreated comparison group within the trial.

Intravenous gene therapy in cats (2026)

A 2026 study gave a single-vector gene therapy into a vein to cats with Sandhoff disease at 1 month of age, before symptoms. Untreated cats lived 4.3 months on average; cats on a low dose lived 8.3 months and cats on a high dose 12.4 months. Treated cats showed marked improvement in the prevention of full-body tremors, had less GM2 storage, and showed liver improvement on ultrasound at the high dose. The authors state that this vector “has not yet been tested in clinical trials.”

Back to Table of Contents

What Is Not Known

• No proven disease-modifying treatment. GeneReviews (2022) states treatment is symptomatic, and the 2023 N-acetyl-L-leucine trial report opens by describing the GM2 gangliosidoses as diseases “with no available symptomatic or disease-modifying treatments.”
• How long gene therapy lasts. In the 2025 trial, biochemical correction was already declining by 24 weeks. Whether repeat dosing, higher doses or earlier treatment changes this is not established, and the worsening dystonia in juvenile patients is not explained in the abstract.
• Sandhoff-only data. Almost every study pools Tay-Sachs and Sandhoff patients. The infantile survey found the two did not differ, but the juvenile and adult series found real differences (more psychiatric disturbance and neuropathy in juvenile Sandhoff, more sensory nerve involvement in adult Sandhoff). Treatment results reported only for the pooled group may not apply equally to both.
• Long-term effect of N-acetyl-L-leucine. The phase IIb trial lasted 6 weeks with no placebo group.
• Whether miglustat changes the course. The human evidence is case reports and small mixed groups; the 2023 review called the earlier results “inconsistent.”
• True frequency worldwide. Rates are known for a few screened communities; the global carrier estimate of 1 in 57 in the Saskatchewan paper comes from 1,092 genomes, a small sample.
• Why the course varies so much. In the juvenile study, the gene variant predicted the course for Tay-Sachs patients; the abstract reports no such pattern for Sandhoff patients.

Back to Table of Contents

Key Research Papers

1. Xiao C, Tifft C, Toro C. Sandhoff Disease. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993–2026. 2022 Apr 14. PubMed PMID: 35420740
2. Bley AE, Giannikopoulos OA, Hayden D, Kubilus K, Tifft CJ, Eichler FS. Natural history of infantile G(M2) gangliosidosis. Pediatrics. 2011;128(5):e1233-41. PubMed PMID: 22025593
3. Tavasoli AR, Parvaneh N, Ashrafi MR, Rezaei Z, Zschocke J, Rostami P. Clinical presentation and outcome in infantile Sandhoff disease: a case series of 25 patients from Iranian neurometabolic bioregistry with five novel mutations. Orphanet J Rare Dis. 2018;13(1):130. PubMed PMID: 30075786
4. Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, Giugliani R, Mahuran D, Clarke JT. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics. 2006;118(5):e1550-62. PubMed PMID: 17015493
5. Masingue M, Dufour L, Lenglet T, Saleille L, Goizet C, Ayrignac X, Ory-Magne F, Barth M, Lamari F, Mandia D, Caillaud C, Nadjar Y. Natural History of Adult Patients with GM2 Gangliosidosis. Ann Neurol. 2020;87(4):609-617. PubMed PMID: 31995250
6. Drousiotou A, Stylianidou G, Anastasiadou V, Christopoulos G, Mavrikiou E, Georgiou T, Kalakoutis G, Oladimeji A, Hara Y, Suzuki K, Furihata K, Ueno I, Ioannou PA, Fensom AH. Sandhoff disease in Cyprus: population screening by biochemical and DNA analysis indicates a high frequency of carriers in the Maronite community. Hum Genet. 2000;107(1):12-7. PubMed PMID: 10982028
7. Fitterer B, Hall P, Antonishyn N, Desikan R, Gelb M, Lehotay D. Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis. Mol Genet Metab. 2014;111(3):382-389. PubMed PMID: 24461908
8. Kleiman FE, de Kremer RD, de Ramirez AO, Gravel RA, Argaraña CE. Sandhoff disease in Argentina: high frequency of a splice site mutation in the HEXB gene and correlation between enzyme and DNA-based tests for heterozygote detection. Hum Genet. 1994;94(3):279-82. PubMed PMID: 8076944
9. Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH, Dwek RA, Platt FM. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1999;96(11):6388-93. PubMed PMID: 10339597
10. Maegawa GH, van Giersbergen PL, Yang S, Banwell B, Morgan CP, Dingemanse J, Tifft CJ, Clarke JT. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. Mol Genet Metab. 2009;97(4):284-91. PubMed PMID: 19447653
11. Tallaksen CM, Berg JE. Miglustat therapy in juvenile Sandhoff disease. J Inherit Metab Dis. 2009;32 Suppl 1:S289-93. PubMed PMID: 19898953
12. Masciullo M, Santoro M, Modoni A, Ricci E, Guitton J, Tonali P, Silvestri G. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J Inherit Metab Dis. 2010;33 Suppl 3:S355-61. PubMed PMID: 20821051
13. Mansouri V, Tavasoli AR, Khodarahmi M, Dakkali MS, Daneshfar S, Ashrafi MR, Heidari M, Hosseinpour S, Sharifianjazi F, Bemanalizadeh M. Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: A systematic review. Eur J Neurol. 2023;30(9):2919-2945. PubMed PMID: 37209042
14. Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, Fineran P, Morten KJ, Poulton J, Boland B, Spencer J, Strupp M, Platt FM. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 2021;3(1):fcaa148. PubMed PMID: 33738443
15. Martakis K, Claassen J, Gascon-Bayari J, Goldschagg N, Hahn A, Hassan A, Hennig A, Jones S, Kay R, Lau H, Perlman S, Sharma R, Schneider S, Bremova-Ertl T. Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses. Neurology. 2023;100(10):e1072-e1083. PubMed PMID: 36456200
16. Clarke JT, Mahuran DJ, Sathe S, Kolodny EH, Rigat BA, Raiman JA, Tropak MB. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab. 2011;102(1):6-12. PubMed PMID: 20926324
17. Flotte TR, Cataltepe O, Puri A, Batista AR, Moser R, McKenna-Yasek D, Douthwright C, Gernoux G, Blackwood M, Mueller C, Tai PWL, Jiang X, Bateman S, Spanakis SG, Parzych J, Keeler AM, Abayazeed A, Rohatgi S, Gibson L, Finberg R, Barton BA, Vardar Z, Shazeeb MS, Gounis M, Tifft CJ, Eichler FS, Brown RH Jr, Martin DR, Gray-Edwards HL, Sena-Esteves M. AAV gene therapy for Tay-Sachs disease. Nat Med. 2022;28(2):251-259. PubMed PMID: 35145305
18. Eichler F, Cataltepe OI, Daci R, Puri AS, Taghian T, Jiang X, Shazeeb MS, Kuhn A, Hader A, Celik H, Vardar Z, Lewis CJ, Artinian R, Nagy A, Vachha B, Thompson R, Gallagher T, Bateman S, Parzych J, Spanakis SG, Vaughn TA, Pier K, De Boever E, Abbott MA, D Ambrosio E, Kokoski D, Blackwood M, Drummond E, Ratai EM, Townsend EL, McLaughlin H, Tifft CJ, Keeler AM, Sena-Esteves M, Gray-Edwards HL, Flotte TR. Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial. Nat Med. 2025;31(9):2927-2935. PubMed PMID: 40817303
19. Maguire AS, Ta NL, Gross AL, Garrett CJ, Zimmerman AD, Diffie EB, Osterhoudt DE, Pacer SH, Mitchell ML, Cannon JS, Hall PI, Sandey M, Cole RC, Seyfried TN, Gray-Edwards HL, Sena-Esteves M, Martin DR. Intravenous gene therapy improves life span and clinical outcomes in a feline model of Sandhoff disease. Sci Transl Med. 2026;18(866):eadx2447. PubMed PMID: 42715347

PubMed Topic Searches

1. PubMed: Sandhoff disease natural history
2. PubMed: HEXB variants and carrier frequency
3. PubMed: GM2 gangliosidosis gene therapy
4. PubMed: GM2 gangliosidosis and miglustat
5. PubMed: N-acetyl-L-leucine in GM2 gangliosidosis

Back to Table of Contents

Connections

• Genetics — the parent category for inherited diseases
• Tay-Sachs Disease — the HEXA sister disease, with hexosaminidase A lost alone
• Niemann-Pick Disease — another lysosomal storage disease of the brain
• Niemann-Pick Type C Treatments — where acetyl-leucine and miglustat are also studied
• Gaucher Disease — the storage disease where substrate reduction began
• Krabbe Disease — another inherited lysosomal disease of the nervous system
• Cerebellar Ataxia — a main sign of the juvenile and late-onset forms
• Amyotrophic Lateral Sclerosis — the motor neuron disease adult cases can resemble
• Serine in Sphingolipid Synthesis — how the body builds the fats that GM2 belongs to

Back to Table of Contents

Featured Videos